USA - NASDAQ:BGLC - US0906283066 - Common Stock
The current stock price of BGLC is 5.09 USD. In the past month the price decreased by -9.91%. In the past year, price increased by 35.73%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| URI | UNITED RENTALS INC | 21.43 | 58.76B | ||
| FAST | FASTENAL CO | 40.07 | 49.22B | ||
| FERG | FERGUSON ENTERPRISES INC | 25.04 | 48.83B | ||
| GWW | WW GRAINGER INC | 24.57 | 46.32B | ||
| AER | AERCAP HOLDINGS NV | 9.97 | 21.24B | ||
| FTAI | FTAI AVIATION LTD | 45.04 | 18.66B | ||
| WSO.B | WATSCO INC -CL B | 29.09 | 15.38B | ||
| WSO | WATSCO INC | 27.78 | 14.69B | ||
| QXO | QXO INC | 114.94 | 12.39B | ||
| WCC | WESCO INTERNATIONAL INC | 18.28 | 10.97B | ||
| CNM | CORE & MAIN INC-CLASS A | 21.51 | 10.79B | ||
| AIT | APPLIED INDUSTRIAL TECH INC | 25.72 | 9.83B |
BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
BIONEXUS GENE LAB CORP
10-2 Tower B, Vertical Business Suite, 8 Jalan Kerinchi
KUALA LUMPUR WILAYAH PERSEKUTUAN MY
Employees: 30
Phone: 13072416898
BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
The current stock price of BGLC is 5.09 USD. The price decreased by -1.93% in the last trading session.
BGLC does not pay a dividend.
BGLC has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
BIONEXUS GENE LAB CORP (BGLC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.63).
BIONEXUS GENE LAB CORP (BGLC) has a market capitalization of 9.16M USD. This makes BGLC a Nano Cap stock.
You can find the ownership structure of BIONEXUS GENE LAB CORP (BGLC) on the Ownership tab.
ChartMill assigns a technical rating of 5 / 10 to BGLC. When comparing the yearly performance of all stocks, BGLC is one of the better performing stocks in the market, outperforming 80.9% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to BGLC. While BGLC has a great health rating, there are worries on its profitability.
Over the last trailing twelve months BGLC reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS decreased by -47.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.21% | ||
| ROE | -39.1% | ||
| Debt/Equity | 0 |